Epidemiological Study to Assess the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Pegylated Liposomal Doxorubicin
18 Years
N/A
Female
Ovarian Neoplasms, Breast Neoplasms, Paresthesia
Trial Information
Epidemiological Study to Assess the Management of Palmar-plantar Erythrodysesthesia (PPE) in Patients With Metastatic Ovarian or Breast Cancer Treated With Pegylated Liposomal Doxorubicin
Inclusion Criteria:
- Women 18 years of age or older.
- Participants with metastatic breast or ovarian cancer who are receiving treatment
with pegylated liposomal doxorubicin.
- Participants who have given their written consent.
Exclusion Criteria:
- Participants who are currently participating in a clinical trial.
Type of Study:
Observational
Study Design:
Observational Model: Case-Only, Time Perspective: Cross-Sectional
Outcome Measure:
Number of Participants Who Received Concomitant Treatment Strategies to Manage Palmar-Plantar Erythrodysesthesia (PPE)
Outcome Description:
Participants treated with Caelyx who developed PPE and the categories of specific treatment strategies that were prescribed to manage the symptoms of PPE. Participants counted under the strategies: Keep Skin Hydrated; Avoid Sweating and Physical Activity; Avoid Tight-Fitting Clothing; Local Cooling of Hands and Feet; were those who either always or sometimes followed it.
Outcome Time Frame:
Participants will do a single visit, but cases will be collected during a period of 12 months.
Safety Issue:
Yes
Authority:
Spain: Spanish Agency of Medicines
Study ID:
P05020
NCT ID:
NCT00746694
Start Date:
October 2007
Completion Date:
June 2009
Related Keywords:
- Ovarian Neoplasms
- Breast Neoplasms
- Paresthesia
- Breast Neoplasms
- Neoplasms
- Ovarian Neoplasms
- Paresthesia
Name | Location |
|---|
